RARE Ultragenyx Pharmaceutical Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RARE

Price (delayed)

$44.86

Market cap

$3.73B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.95

Enterprise value

$3.66B

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of ...

Highlights
RARE's EPS is up by 22% year-on-year and by 3.6% since the previous quarter
The revenue rose by 15% year-on-year
Ultragenyx Pharmaceutical's debt has increased by 43% YoY but it has decreased by 6% from the previous quarter
The equity has declined by 49% since the previous quarter and by 36% year-on-year
The quick ratio has decreased by 32% YoY and by 10% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ultragenyx.com
Peers: FOLD ESPR BMRN LXRX

Key stats

What are the main financial stats of RARE
Market
Shares outstanding
83.13M
Market cap
$3.73B
Enterprise value
$3.66B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
26.33
Price to sales (P/S)
8.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.26
Earnings
Revenue
$442.59M
EBIT
-$615.22M
EBITDA
-$585.6M
Free cash flow
-$531.11M
Per share
EPS
-$7.95
Free cash flow per share
-$6.3
Book value per share
$1.7
Revenue per share
$5.25
TBVPS
$13.02
Balance sheet
Total assets
$1.31B
Total liabilities
$1.17B
Debt
$40.76M
Equity
$140.26M
Working capital
$350.39M
Liquidity
Debt to equity
0.29
Current ratio
2.43
Quick ratio
2.09
Net debt/EBITDA
0.12
Margins
EBITDA margin
-132.3%
Gross margin
88.6%
Net margin
-138.6%
Operating margin
-131.3%
Efficiency
Return on assets
-45.9%
Return on equity
-425.6%
Return on invested capital
-78%
Return on capital employed
-58%
Return on sales
-139%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RARE stock price

How has the Ultragenyx Pharmaceutical stock price performed over time
Intraday
-0.44%
1 week
5.43%
1 month
10.68%
1 year
6.45%
YTD
-6.19%
QTD
9.15%

Financial performance

How have Ultragenyx Pharmaceutical's revenue and profit performed over time
Revenue
$442.59M
Gross profit
$392.1M
Operating income
-$581.1M
Net income
-$613.35M
Gross margin
88.6%
Net margin
-138.6%
Ultragenyx Pharmaceutical's net margin has increased by 26% YoY
The company's operating margin rose by 25% YoY
The revenue rose by 15% year-on-year
Ultragenyx Pharmaceutical's net income has increased by 15% YoY

Growth

What is Ultragenyx Pharmaceutical's growth rate over time

Valuation

What is Ultragenyx Pharmaceutical stock price valuation
P/E
N/A
P/B
26.33
P/S
8.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.26
RARE's EPS is up by 22% year-on-year and by 3.6% since the previous quarter
RARE's price to book (P/B) is 103% more than its 5-year quarterly average of 13.0 but 28% less than its last 4 quarters average of 36.8
The equity has declined by 49% since the previous quarter and by 36% year-on-year
The P/S is 48% lower than the 5-year quarterly average of 16.6 but 10% higher than the last 4 quarters average of 7.8
The revenue rose by 15% year-on-year

Efficiency

How efficient is Ultragenyx Pharmaceutical business performance
The ROE has dropped by 155% year-on-year and by 15% since the previous quarter
RARE's return on sales is up by 25% year-on-year
The return on assets has increased by 6% year-on-year but it has declined by 2.7% since the previous quarter
The company's return on invested capital fell by 5% QoQ but it rose by 4.6% YoY

Dividends

What is RARE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RARE.

Financial health

How did Ultragenyx Pharmaceutical financials performed over time
The total assets is 12% more than the total liabilities
The quick ratio has decreased by 32% YoY and by 10% QoQ
The current ratio is down by 31% YoY and by 7% QoQ
Ultragenyx Pharmaceutical's debt is 71% less than its equity
Ultragenyx Pharmaceutical's debt to equity has soared by 123% YoY and by 81% from the previous quarter
The equity has declined by 49% since the previous quarter and by 36% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.